BioNTech (NASDAQ:BNTX) PT Lowered to $101.00

BioNTech (NASDAQ:BNTX) had its target price decreased by equities research analysts at UBS Group from $110.00 to $101.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. UBS Group’s price target would indicate a potential upside of 9.49% from the stock’s previous close.

BNTX has been the subject of a number of other research reports. The Goldman Sachs Group cut their price objective on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. JPMorgan Chase & Co. cut their target price on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a report on Friday, March 22nd. BMO Capital Markets lowered their price objective on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a research report on Thursday, March 21st. Oppenheimer initiated coverage on shares of BioNTech in a research report on Friday, January 5th. They set a “market perform” rating on the stock. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $171.00 price objective on shares of BioNTech in a research note on Thursday, March 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $120.40.

BioNTech Price Performance

Shares of BioNTech stock opened at $92.25 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. The stock has a market capitalization of $21.93 billion, a P/E ratio of 22.39 and a beta of 0.23. BioNTech has a one year low of $85.21 and a one year high of $131.52. The business’s 50 day simple moving average is $93.41 and its two-hundred day simple moving average is $99.54.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BNTX. PNC Financial Services Group Inc. raised its stake in shares of BioNTech by 207.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,583 shares of the company’s stock valued at $273,000 after acquiring an additional 1,743 shares during the period. Goldman Sachs Group Inc. grew its stake in BioNTech by 17.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock worth $19,301,000 after purchasing an additional 26,777 shares in the last quarter. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV lifted its stake in BioNTech by 26.1% in the fourth quarter. Investmentaktiengesellschaft Fuer Langfristige Investoren TGV now owns 14,500 shares of the company’s stock worth $1,530,000 after acquiring an additional 3,000 shares during the period. Virtu Financial LLC purchased a new stake in BioNTech during the fourth quarter worth $274,000. Finally, Price T Rowe Associates Inc. MD grew its stake in BioNTech by 2.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 62,157 shares of the company’s stock valued at $6,561,000 after purchasing an additional 1,544 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.